New Results

SARS-CoV-2 is sensitive to type I interferon pretreatment

Kumari G. Lokugamage, Adam Hage, Craig Schindewolf, Ricardo Rajsbaum, Vineet D. Menachery
doi: https://doi.org/10.1101/2020.03.07.982264

Article usage

Article usage: March 2020 to November 2023

AbstractFullPdf
Mar 202053935293602
May 202051634602580
Jun 20201683174937
Jul 20202203137978
Aug 202084075484
Sep 2020853137361
Oct 2020152255419
Nov 2020603141235
Dec 202052097236
Jan 202161861238
Feb 202141736135
Mar 202150523187
Apr 202142014132
May 202139312130
Jun 202139321113
Jul 20212491790
Aug 202133216120
Sep 20213471596
Oct 202129812114
Nov 202123614120
Dec 2021235552
Jan 2022230360
Feb 2022187958
Mar 20221961671
Apr 2022196563
May 20221801266
Jun 2022193359
Jul 2022199448
Aug 2022147242
Sep 2022216539
Oct 2022177640
Nov 2022146841
Dec 2022152945
Jan 20232102454
Feb 20231031345
Mar 20231441059
Apr 202373358
May 202399835
Jun 202371436
Jul 202365321
Aug 202382432
Sep 2023128529
Oct 20232881435
Nov 20235111536
Back to top
Posted April 09, 2020.
Download PDF
Email
SARS-CoV-2 is sensitive to type I interferon pretreatment
Kumari G. Lokugamage, Adam Hage, Craig Schindewolf, Ricardo Rajsbaum, Vineet D. Menachery
bioRxiv 2020.03.07.982264; doi: https://doi.org/10.1101/2020.03.07.982264
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area